Researchers at Charité — Universitätsmedizin Berlin conducted a clinical trial examining whether dronabinol, a prescription medication containing THC derived from cannabis, could effectively treat nightmares associated with post-traumatic stress disorder. Nightmares represent one of the most distressing PTSD symptoms, often causing severe sleep disruption and creating fear of sleep itself. Traditional medications such as antidepressants and blood pressure-lowering drugs offer limited relief from trauma-related nightmares, leaving a significant treatment gap.
The study involved more than 170 individuals with PTSD experiencing frequent, severe nightmares. Participants received either dronabinol administered as evening drops or an identical-appearing placebo for ten weeks in a double-blind, placebo-controlled trial design. Researchers hypothesized that THC’s interaction with the body’s endocannabinoid system—which regulates sleep, stress response, and emotional memory processing—could reduce dream activity during REM sleep and thereby alleviate nighttime trauma responses.
Results demonstrated substantial differences between treatment groups. Participants receiving dronabinol experienced an average nightmare severity reduction of 3.7 points on an eight-point scale, compared to 2.2 points in the placebo group. More than one-third of dronabinol recipients reported complete cessation of nightmares, while an additional 21 percent reported at least a 50 percent reduction in nightmare burden. Approximately five out of six patients in the treatment group reported marked overall health improvement.
The medication appeared to work specifically on nightmares and sleep quality rather than addressing broader PTSD symptoms or accompanying depression. Mild to moderate side effects including dizziness, headaches, and increased appetite occurred more frequently in the dronabinol group, though no severe adverse effects were documented. Researchers found no withdrawal symptoms when participants discontinued the medication at study conclusion.
The research team indicated that future investigations will assess long-term safety and efficacy, as well as whether patients develop tolerance over extended treatment periods. Multiple German institutions participated in the work, which was published in Nature Medicine.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI